Disease relevance of TINP1

• Hairy cell leukemia with chylous ascites [1].
• Hairy cell leukemia-associated familial lymphoproliferative disorder: immunologic abnormalities in unaffected family members [2].
• Hairy-cell leukemia and aplastic anemia [3].
• Hairy cell leukemia (HCL) is frequently associated with severe pancytopenia [4].
• Hairy cell leukemia (leukemic reticuloendotheliosis): chemotherapy for splenectomy failures [5].

Psychiatry related information on TINP1

• Hairy cell leukemia is a lymphoreticular malignancy characterized by a chronic course and multiple defects in host defense mechanisms [6].

High impact information on TINP1

• BACKGROUND: Hairy-cell leukemia that is resistant to treatment with purine analogues, including cladribine, has a poor prognosis [7].
• Hairy-cell leukemia and glucose-6-phosphate dehydrogenase deficiency in two brothers [8].
• Hairy-cell leukemia treated with lithium [9].
• Hairy cell leukemia (HCL) is a chronic B cell malignancy characterized by the diffuse infiltration of bone marrow and spleen by cells displaying a typical "hairy" morphology [10].
• Hairy cell leukemia (HCL) commonly expresses multiple immunoglobulin isotypes, a feature rare in other B-cell malignancies or in normal B cells [11].

Chemical compound and disease context of TINP1

• Hairy-cell leukemia is characterized clinically in splenomegaly and pancytopenia and pathologically by the proliferation in hematopoietic tissue of cells containing the tartrate-resistant isozyme 5 of acid phosphatase [12].
• Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia [13].
• Cladribrine (2-CdA), a purine analogue active on both dividing and resting lymphocytes, plays an important role in the treatment of indolent lymphoproliferative malignancies such as Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Lymphoplasmocytic Lymphoma (LPL), Waldenström's Macroglobulinemia (WM) [14].
• BACKGROUND AND OBJECTIVE: Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative disorder which is treated effectively by interferon-alpha (IFN-alpha), deoxycoformycin (DCF) and 2-clorodeoxyadenosine (2-CdA) [15].
• Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusions [16].

Biological context of TINP1

• Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions [17].
• Hairy cell leukemia: an interphase cytogenetic study [18].
• Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype [19].
• Hairy cell leukemia: a reversible disease? A report of two cases of spontaneous remission [20].
• Hairy cell leukemia and occupational exposures [21].

Anatomical context of TINP1

• Hairy cell leukemia is a chronic B-cell disorder that follows an indolent, but progressive course [22].
• Hairy-cell leukemia with T-cell features [23].
• Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment [24].
• Hairy-cell leukemia has been associated with a number of disorders of the immune system [25].
• Hairy cell leukemia is characterized by monocyte dysfunction and such patients have a predilection for infection by microbes that are controlled by cell-mediated defenses [26].

Associations of TINP1 with chemical compounds

• Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin) [27].
• Hairy cell leukemia: results of 2-chlorodeoxyadenosine therapy in Jerusalem [28].
• Hairy cell leukemia responsive to chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) [29].
• Peripheral blood lymphocytes (PBL) of eleven patients with Hairy Cell Leukemia were studied for surface phenotype and for NK activity against the K 562 cell line (using both the standard 51Cr Release Assay and the Single Cell Cytotoxicity Assay on poly-L-lysine coated coverslips) [30].

Physical interactions of TINP1

• Electrophoretic mobility shift assays and mutational analyses demonstrated that the perlecan TGF-beta-responsive element bound specifically to TGF-beta-inducible nuclear proteins with high affinity for NF-1 member(s) of transcription factors [31].

Other interactions of TINP1

• Since the application of low doses of IFN-alpha is necessary to maintain remissions in Hairy Cell Leukemia (HCL) it is of interest whether peripheral blood mononuclear cells (MNC) of HCL patients can be induced in vitro to produce IFN-alpha [32].
• Hairy cell leukemia (HCL) differed from CLL in its tendency to lack VLA-2, in its consistent lack of VLA-3, and altogether resembled splenic EF in its VLA profile [33].
• Hairy cell leukemia is a chronic lymphoproliferative disorder of B-cell lineage, whose malignant cells express the interleukin-2 (IL-2) receptor [34].
• Central Role of Protein Kinase C{epsilon} in Constitutive Activation of ERK1/2 and Rac1 in the Malignant Cells of Hairy Cell Leukemia [35].
• Hairy cell leukemia-associated antigen LeuM5 (CD11c) is preferentially expressed by benign activated and neoplastic CD8 T cells [36].

Analytical, diagnostic and therapeutic context of TINP1

• Hairy cell leukemia: splenectomy after alpha-interferon therapy [37].
• Human lymphoblastoid interferon as initial therapy in hairy cell leukaemia: a multicentre study in non-splenectomized patients. Italian Cooperative Group for Hairy Cell Leukemia [38].
• Hairy cell leukemia: a retrospective study of 235 cases by the Italian Cooperative Group (ICGHCL) according to Jansen's clinical staging system [39].
• Hairy cell leukemia: A diagnosis by endoscopic ultrasound guided fine needle aspiration [40].
• Hairy cell leukemia: early immunophenotypical detection and quantitative analysis by flow cytometry [41].

References